The type 2 isoform of human 17␤-hydroxysteroid dehydrogenase (17␤HSD2) efficiently catalyzes the oxidative metabolism of androgens and estrogens, and it is expressed in a large series of human peripheral tissues. To obtain a better understanding of the regulation of local steroid biosynthesis and metabolism in human tissues, we have established a dual steroidogenic activity of the 17␤HSD2 enzyme after transfection of human 17␤HSD2-transfected human embryonic kidney (293) cells. After transient transfection, the metabolism of testosterone, pregnenolone, and dehydroepiandrosterone (DHEA) in intact transfected 293 cells was evaluated by TLC-based radiometric assays. 17␤HSD2-transfected cells converted 91% of testosterone (1 mol/L) into androstenedione in a 2-h incubation period. In addition, pregnenolone (1 mol/L) was converted to progesterone (18.5%), whereas DHEA (1 mol/L) was metabolized to androstenedione (8.3% conversion) in a 15-h incubation period. The kinetics of the 3␤-hydroxysteroid dehydrogenase (3␤HSD) and 17␤HSD2 activities using cell homogenate protein of stably transfected 293 cells indicated that the catalytic efficiency (apparent catalytic efficiency ϭ maximum velocity/K m ) of this 3␤HSD activity is approximately 2000-fold (pregnenolone as substrate) or 3000-fold (DHEA as substrate) weaker than that of 17␤HSD2 activity. It is noteworthy, however, that the apparent catalytic efficiency of the HSD3B2 gene product is only approximately 50-fold higher than that of the 3␤HSD aspect of the 17␤HSD2 gene product. Pregnenolone or DHEA effectively inhibited 17␤HSD2 activity in a noncompetitive fashion. Furthermore, the potent 5␣-reductase/3␤HSD inhibitor, 17␤-N,N-diethylcarbamoyl-4-methyl-4-aza-5␣-androstane-3-one, inhibited neither 3␤HSD nor 17␤HSD2 activities. We conclude that human 17␤HSD2 enzyme exhibits 3␤HSD activity. Notwithstanding that this 3␤HSD activity is reduced compared to 17␤HSD oxidative activity, it may account for at least some of the reports of 3␤HSD activity found in human peripheral tissues that express notable amounts of the 17␤HSD2 isozyme as well as in individuals with severe classic 3␤HSD deficiency. (J Clin Endocrinol Metab 85: 3669 -3672, 2000) 
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7␤-HYDROXYSTEROID dehydrogenase (17␤HSD) enzymes, which catalyze the reversible reactions between estrone and estradiol and between androstenedione and testosterone, are believed to play essential roles in regulation of the tissue levels of bioactive steroids. In recent years various isoforms of 17␤HSD have been identified (1) (2) (3) (4) , and it is revealed that 17␤-reduction and oxidation of androgens and estrogens are catalyzed by different isozymes. 17␤HSD type 1 catalyzes the 17␤-reduction of estrogens (1) , type 3 is the most efficient in the reduction of testosterone to androstenedione (3), whereas 17␤HSD type 2 (17␤HSD2) is NAD ϩ dependent and efficiently catalyzes the oxidative metabolism of estrogens and androgens (2) . 17␤HSD2 enzyme is expressed in a large series of human peripheral tissues, including the placenta, liver, pancreas, kidney, small intestine, and secretory endometrium (5) , and it is believed to be a key enzyme in the transformation of bioactive steroids to inactive compounds locally.
The findings of recent investigations have demonstrated that some oxidoreductase enzymes show dual steroidogenic activity (6 -9) . 17␤HSD2 was also reported to exhibit 20␣-hydroxysteroid dehydrogenase (20␣HSD) activity (2) . To obtain a deeper understanding of the regulation of local steroid biosynthesis and metabolism in human tissues, it is important to examine such multiple steroidogenic activities of 17␤HSD enzymes in detail. In this study we have investigated the possibility that human 17␤HSD2 possesses other steroidogenic activities, using the recombinant enzyme expressed in nonsteroidogenic human embryonic kidney 293 cells.
Materials and Methods

Vector and plasmid
The pCMV6 vector containing the full-length complementary DNA (cDNA) encoding the complete amino acid sequence for human 17␤HSD2 was used (2) .
Enzymatic activity assay in intact cells
To determine enzymatic activity in intact transfected 293 cells, plasmids were transiently transfected into 293 cells plated in 24-well cell culture clusters (Costar, Cambridge, MA), using lipofectin reagent (Life Technologies, Inc., Gaithersburg, MD). Seventy-two hours after transfection, cells were directly incubated at 37 C with 0. 5 
Enzymatic activity assay in cell homogenates
To obtain further information of the enzymatic activities, we also performed in vitro examinations using homogenized transfected 293 cells. After cotransfection of the 17␤HSD2 plasmid with a pcDNA3.1 plasmid (Invitrogen, San Diego, CA) that contained the neomycin resistance gene using lipofectin reagent (Life Technologies, Inc.), selection of stable transfectants using G418 (Life Technologies, Inc.; 0.5 mg/mL) was achieved after at least three cell passages. Cells were cultured in Falcon's 100 ϫ 20-mm tissue culture dishes (Becton Dickinson and Co., Lincoln Park, NJ), harvested in the logarithmic growth phase, and rinsed with phosphate-buffered saline (pH 7.4), and the protein was collected with assay buffer (12 mmol/L Tris, 1 mmol/L ethylenediamine tetraacetate, and 0.25 mol/L sucrose) before homogenization. As negative controls, nontransfected 293 cells were used. The protein concentration was measured by the method of Lowry, using the Coomassie protein assay reagent (Pierce Chemical Co., Rockford, IL).
The cell homogenate protein was incubated at 37 C in 500 L assay buffer containing the indicated concentration of 3 H-labeled steroids (5 ϫ 10 4 cpm/500 L assay buffer) and NAD ϩ (1 mmol/L) as cofactor in the presence or the absence of the various unlabeled competitor steroid. Cell homogenates were also incubated in the presence of the 5␣-reductase/ 3␤HSD inhibitor, 17␤-N,N-diethylcarbamoyl-4-methyl-4-aza-5␣-androstane-3-one (4MA; 1 mol/L). As a positive control of 3␤HSD activity, 293 cells stably transfected with cDNA for human 3␤HSD type 2 (3␤HSD2) (10) were also used (10).
Extraction, separation, and quantification of steroids
In each experiment after the indicated incubation period the enzymatic reaction was terminated by addition of methylene chloride (6 mL). The organic phase was concentrated under a steam of nitrogen and separated by TLC on silica gel 60 plates (Merck & Co., Inc., Darmstadt, Germany) in a chloroform/ethyl acetate (4:1, vol/vol) system. Then the rates of product formation were compared using an Imaging Scanner System 200 (Bioscan, Inc., Washington, DC). Apparent K m and maximum velocity (V max ) values were calculated by Lineweaver-Burk analysis.
Results
Enzymatic activities of human 17␤HSD2 in intact transfected 293 cells
We first the analyzed enzymatic activity of human 17␤HSD2 in intact transfected 293 cells after TLC analysis. When we incubated 17␤HSD2-transfected cells with testosterone (1 mol/L) as substrate, these cells demonstrated high 17␤HSD2 activity, i.e. in a typical experiment, conversion rates were 35.9%, 74.6%, 86.1%, and 90.7% of testosterone to androstenedione in 0.5-, 1-, 1.5-, and 2-h incubation periods, respectively. We also used mock-transfected cells as a negative control, in which only 2.1% conversion was detected in a 2-h incubation period. When 17␤HSD2-transfected cells were incubated with pregnenolone (1 mol/L), 3␤HSD activity was detected, and the substrate was converted to progesterone in yields of 5.7% and 18.5% in 6-and 15-h incubation periods, respectively. There was no detectable progesterone formation in mock-transfected cells in a 15-h period of incubation (Ͻ0.1%). The identity of the radiolabeled progesterone product was confirmed by recrystallization studies to demonstrate a constant specific activity (data not shown). DHEA (1 mol/L) was also converted to androstenedione in 6-h (3.5%) and 15-h (8.3%) incubation periods, respectively, whereas no conversion was observed in mock-transfected cells in a 15-h incubation period. To obtain further information about this 3␤HSD activity of 17␤HSD2 enzyme, we performed the following in vitro experiments using cell homogenates.
Kinetic properties of 17␤HSD2 and 3␤HSD activities of human 17␤HSD2 enzyme
First, we examined the kinetic properties of 17␤HSD2 and 3␤HSD activities of human 17␤HSD2 enzyme. As illustrated in Table 1 , the apparent V max of the 3␤HSD activity was much lower than that of 17␤HSD2 activity [3.6 Ϯ 1.8 pmol/min⅐mg protein (pregnenolone as substrate) or 3.8 Ϯ 0.4 pmol/ min⅐mg protein (DHEA as substrate) for 3␤HSD activity, and 4670 Ϯ 640 pmol/min⅐mg protein for 17␤HSD2 activity]. The 3␤HSD apparent catalytic efficiency (apparent V max /apparent K m ) was 2000-to 3000-fold weaker than that for 17␤HSD. As negative controls, we used homogenates of nontransfected 293 cells under the same conditions, but no activities were detected.
Competition by 3␤HSD substrates of 17␤HSD2 activity
To analyze whether these activities have a similar catalytic site on human 17␤HSD2 protein, we next performed competition experiments for 17␤HSD2 activity, using 3␤HSD substrates. As illustrated in Fig. 1 , when homogenate protein (10 g) was incubated with radiolabeled testosterone (0.1 mol/L), in the presence of various concentrations of nonradiolabeled competitors, pregnenolone and DHEA inhibited 17␤HSD2 activity with IC 50 values of 4.5 mol/L for pregnenolone, and 9.5 mol/L for DHEA (the corresponding IC 50 value after testosterone addition was 2.0 mol/L). Lineweaver-Burk analysis of the competition by 3␤HSD substrates of 17␤HSD2 activity using testosterone as substrate are demonstrated in Fig. 1, A and B. Apparent K m (micromolar concentrations) and V max (nanomoles per min/mg protein) values at each inhibitor concentration were as follows: testosterone only (no inhibitor), 2.3 and 4.0; 0.1 mol/L pregnenolone, 2.0 and 3.2; 1 mol/L pregnenolone, 2.1 and 2.3; 10 mol/L pregnenolone, 3.1 and 1.9; 100 mol/L pregnenolone, 3.0 and 1.3; 0.1 mol/L DHEA, 2.1 and 3.5; 1 mol/L DHEA, 2.0 and 2.3; 10 mol/L DHEA, 2.2 and 2.1; and 100 mol/L DHEA, 2.6 and 1.2. These data indicate that the apparent K m value is constant, whereas the apparent V max value is decreased as the competitor steroid concentration is increased, suggesting that pregnenolone and DHEA, substrates of 3␤HSD, inhibit 17␤HSD2 activity in a noncompetitive manner.
Effects of 17␤-N,N-diethylcarbamoyl-4-methyl-4-aza-5␣-androstane-3-one (4MA) on 3␤HSD activity of human 17␤HSD2 enzyme
4MA is known as a potent 3␤HSD inhibitor, especially inhibiting dehydrogenase activity (11) . We examined the effect of 4MA on dual activities of the human 17␤HSD2 enzyme.
As shown in Fig. 2A, 4MA (1 mol/L) strongly inhibited both 3␤HSD reactions of human 3␤HSD2-transfected 293 cells (P Ͻ 0.001). Nevertheless, 4MA (1 mol/L) inhibited neither 3␤HSD (Fig. 2B) nor 17␤HSD2 (Fig. 2C ) activity in 17␤HSD2-transfected cells.
Discussion
Our study demonstrates that 17␤HSD2 enzyme exhibits 3␤HSD activity in both intact cells and cell homogenate protein of transfected 293 cells. The oxidative pathway of 17␤HSD activity (estradiol to estrone, and testosterone to androstenedione) is detected in almost all human peripheral tissues (12) . It has been demonstrated that 17␤HSD2 enzyme is expressed in a large series of human peripheral tissues, including the placenta, liver, pancreas, kidney, small intestine, and secretory endometrium, and it is regulated by progestins (5). In our study although 17␤HSD2-associated 3␤HSD activity is low compared to oxidative 17␤HSD2 activity, these findings support the idea that the 17␤HSD2 enzyme in various human peripheral tissues exhibits 3␤HSD activity.
It is well known that the adrenals, ovaries, and testes are the major source of androgens and estrogens in humans, but in addition, peripheral tissues can synthesize bioactive sex steroids locally (12, 13) . 3␤HSD is a crucial step in the biosynthesis of hormonal steroids. 3␤HSD activity is found not only in classical steroidogenic tissues, but also in a large series of peripheral tissues, where it contributes to the local formation of bioactive sex steroids (13) . Two types of human 3␤HSD genes have been characterized (14, 15) . Human 3␤HSD type 1 (3␤HSD1) gene expression is detected in the placenta, skin, and mammary gland (15) , whereas 3␤HSD2 gene is expressed in the adrenal and gonad (14) . However, 3␤HSD gene expression in other human tissues is uncertain. Milewich et al. (16) reported that 3␤HSD activity is easily demonstrated widely among peripheral tissues of the human fetus, although 3␤HSD protein was not readily detected by Western analysis. Our present data may account for the some of the 3␤HSD activity found in some human peripheral tissues, and 17␤HSD2 enzyme may have a broad role in the regulation of local steroid biosynthesis as well as metabolism. Furthermore, our studies demonstrate that 3␤-hydroxysteroids, e.g., pregnenolone and DHEA, can alter 17␤HSD2 activity. Therefore, the 3␤-hydroxysteroids are possible modulators of 17␤HSD2 activity locally.
The amount of 17␤HSD2 messenger ribonucleic acid is extremely high in human placenta (2). Wu et al. (2) also reported that this enzyme possesses 20␣HSD activity and suggested that it may be important in maintaining high progesterone levels during pregnancy. Our data are in agreement with such an interpretation, and this secondary 3␤HSD activity of 17␤HSD2 may have a role to maintain a high level of progesterone during pregnancy, in cooperation with the 3␤HSD1 enzyme and the 20␣HSD activity of the 17␤HSD2 enzyme. This second activity of 17␤HSD2 may also be important in the formation of 3-ketosteroids in peripheral tissues of individuals with severe classic 3␤HSD deficiency (17) .
The dual activity of certain steroid-specific oxidoreductatases has been reported using a preparation of purified enzymes, e.g., 3␣,20␤HSD from Streptomyces hydrogenans (6), 17␤,20␣HSD from human placenta (7), and 3␤,20␣HSD from fetal lamb blood (4). de Launoit et al. (9) demonstrated that recombinant rat 3␤HSD enzyme also exhibits androgenic 17␤HSD activity using transfected cells. As such secondary activity was suggested to be involved in the original active site in these previous experiments, it was postulated that some steroids can bind in opposite ways to the same enzyme site (8, 18) . However, in our kinetic analysis, substrates of 3␤HSD inhibit 17␤HSD2 activity not in a competitive but in a noncompetitive fashion. These data indicate that the catalytic site of 3␤HSD activity is not closely involved with the 17␤HSD2 active site. In addition, we have shown that 4MA, which competitively and reversibly inhibits dehydrogenase activities of the human 3␤HSD gene products (11), does not inhibit the 3␤HSD activity of 17␤HSD2 protein, thus suggesting that this 3␤HSD activity does not have a typical 3␤HSD active site. To establish the characteristics of the 3␤HSD active site on human 17␤HSD2 protein in more detail, further detailed examination will be necessary.
